INTRODUCTION

Gamma-delta T cells represent a small subset of normal human T cells that possess a distinct T-cell receptor (TCR) on their surface. Their exact function
has not yet been determined, but these cells are known to play a role in both the adaptive and innate immune system. 1 The World Health Organization currently recognizes 2 subtypes of gd T-cell lymphoma, primary cutaneous gd T-cell lymphoma and hepatosplenic gd T-cell lymphoma, 2 both of which are rare. Primary cutaneous gd T-cell lymphoma has an aggressive clinical behavior and poor prognosis, with a meager response to multiagent chemotherapy. However, with the advent of detecting TCR-gd in paraffin-embedded sections, a few reports have shown examples of indolent gd T-cell proliferations within the skin, namely in pityriasis lichenoides (PL) and lymphomatoid papulosis (LyP). [3] [4] [5] In contrast to primary cutaneous gd T-cell lymphoma, a retrospective study of TCR-gd expression in cases of PL and LyP found that such cases have a benign clinical course, with most patients achieving eventual resolution of the lesions and none having lymphoma. 4 Here we describe such an example, with a rare case of gd LyP type D histopathologically mimicking primary cutaneous gd T-cell lymphoma but having an indolent clinical course. This case further highlights the expanding classification scheme of LyP and aims to bring awareness to this newly described entity to allow distinction from primary cutaneous gd T-cell lymphoma.
CASE REPORT
An otherwise healthy 46-year-old white woman presented with a 3-month history of a rash, primarily on the extremities. The lesions began as erythematous papules, which eventually ulcerated and then self-resolved. The patient denied pruritus or tenderness associated with the lesions and had no systemic symptoms. She was initially treated with a 3-week course of prednisone with mild improvement. Outside biopsy found a markedly atypical lymphoid infiltrate composed of T cells that were weakly CD8 1 , positive for granzyme and TIA-1, and TCR-bF -. The cells also expressed TCR-g and TCR-d, leading to a diagnosis of primary cutaneous gd T-cell lymphoma. The patient was subsequently referred to our institution for further workup. At the time of presentation to our clinic, most of her lesions had resolved with only a few erythematous papules remaining on the forearms and lower legs (Fig 1) .
Repeat biopsy of the left forearm found an atypical epidermotropic lymphoid infiltrate expressing CD2, CD3, CD7, CD8, TIA-1, CD30, diminished CD5, TCR-g, TCR-d, and lack of CD4 and bF1 (Fig 2, A-C metabolic panel, and lactate dehydrogenase were significant only for mildly elevated liver function. Flow cytometry showed 17% of the total T-cell population expressing TCR-gd, with an absolute count of 221 cell/L. The immunophenotype of the gd TCR expressing cells was not aberrant:
1 (diminished), CD57 1 (subset), and TCR-gd. They were CD4 -, CD19 -, CD26 -, CD38 -, and negative for TCR-ab. After review with the hematology/oncology department, this minor increase in gd T cells was deemed physiologic. Peripheral blood smear showed only rare atypical large granular lymphocytes. Polymerase chain reaction for T-cell receptor gene rearrangement performed on the peripheral blood was negative for any clonal TRG gene rearrangement or T-cell clones. Put together, these findings ruled out peripheral involvement of a lymphoproliferative process. The patient declined systemic treatment. She continues to get intermittent, small, erythematous papules that last approximately 1 month and then self-resolve without treatment. She follows regularly with the hematology/oncology and dermatology departments and will have repeat testing for complete blood count with differential, metabolic panel, lactate dehydrogenase and leukemia/lymphoma immunophenotyping annually. At 10-month follow-up, the patient had no evidence of systemic disease.
DISCUSSION
Primary cutaneous gd T-cell lymphoma accounts for less than 1% of all cutaneous T-cell lymphomas. Patients typically experience extranodal and nodal dissemination, with 5-year overall survival rates ranging from 11% to 15%. This lymphoma typically presents with plaques, tumors, ulcers, or panniculitis. Histologically, the lesions are typically composed of atypical medium-to-large sized lymphocytes expressing CD3 and CD2, with variable expression of C7 and CD56, and strong positivity for cytotoxic proteins such as granzyme B, perforin, and TIA-1. CD8 positivity is seen rarely, but most cases are negative for both CD4 and CD8. The T cells express the gd receptor by definition and are negative for TCR-bF1. [6] [7] [8] Our patient showed these histopathologic features; however, the atypical lymphocytes showed epidermotropism and were CD30
1 and CD8
1 . Epidermotropism and CD30 positivity are common in LyP type D but would typically not occur in gd T-cell lymphoma. The complete histologic picture as well as the clinical course of relapsing and remitting erythematous papules and lack of systemic symptoms led to the ultimate diagnosis of LyP, specifically LyP type D.
LyP is a chronic, recurrent, CD30 1 lymphoproliferative disorder with various histopathologic subtypes (A-F), described. The diagnosis of LyP can be histologically challenging because of its variability and overlapping features of other cutaneous lymphomas. Clinical correlation is crucial for diagnosis and appropriate management. Type D is a rare subtype of LyP, typically composed of CD8 1 T cells, which can histologically mimic aggressive epidermotropic CD8
1 cytotoxic T-cell lymphoma. 9, 10 Although LyP type D is rare, the expression of TCR-gd is even more uncommon. This type of LyP was first reported by Morimura et al 3 in 2011, and subsequently TCR-gd expression has been found in a few additional cases of PL and LyP. [3] [4] [5] To date, all reported cases have shown an indolent course (follow-up ranging from 3-64 months).
With advancing immunohistochemistry and gene rearrangement techniques, more cases of gd LyP type D will likely emerge. Clinical awareness of this indolent entity is prudent given the poor prognosis of primary cutaneous gd T-cell lymphoma. Unlike patients with primary cutaneous gd T-cell lymphoma, patients with LyP do well and do not require aggressive intervention. However, as with other cases of LyP, patients require long-term follow-up and should be routinely screened for other systemic lymphomas. Although histologically similar, the clinical behavior of gd LyP type D differs greatly from that of primary cutaneous gd T-cell lymphoma. This newly described entity should be kept in mind, as clinicopathologic correlation is necessary for correct diagnosis. 
